188586-91-6

Basic information

• Product Name: methyl 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl) acetate
• Synonyms: methyl 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl) acetate
• CAS NO: 188586-91-6
• Molecular Weight: 310.307
• Mol File: 188586-91-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl) acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl) acetate(188586-91-6)
• EPA Substance Registry System: methyl 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl) acetate(188586-91-6)

Safety Data

• Hazardous Substances Data: 188586-91-6(Hazardous Substances Data)

Upstream product

• 2835-06-5 phenylglycin 
• 24424-99-5 di-tert-butyl dicarbonate 
• 54895-27-1 D-2-tert-butoxycarbonylamino-2-(3-nitrophenyl)-acetic acid 
• 74-88-4 methyl iodide 
• 2935-35-5 (S)-2-phenylglycine 
• 30077-08-8 d-α-amino-m-nitrophenylacetic acid 
• 687631-80-7 methyl 2-amino-2-(3-nitrophenyl)acetate 

Downstream Products

• 140373-23-5 2-((tert-butoxycarbonyl)amino)-2-(3-nitrophenyl)ethyl methanesulfonate 
• 1454273-80-3 tert-butyl (2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)-1-(3-nitrophenyl)ethyl)carbamate 
• 1454273-81-4 tert-butyl (1-(3-aminophenyl)-2-(1-(2-fluoro-6-(trifluoromethyI)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)carbamate 
• 1454273-82-5 ethyl 4-((3-(1-((tert-butoxycarbonyl)amino)-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1 H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenyl)amino)butanoate 
• 180081-34-9 methyl 2-(3-aminophenyl)-2-((tert-butoxycarbonyl)amino)acetate 
• 1454273-37-0 N-(3-(1-amino-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenyl)acetamide 
• 1454273-86-9 tert-butyl (1-(3-acetamidophenyl)-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)carbamate 
• 1454273-36-9 1-(3-(1-amino-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenyl)-3-methylurea 
• 1454273-85-8 tert-butyl (2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)-1-(3-(3-methylureido)phenyl)ethyl)carbamate 
• 1454273-84-7 tert-butyl (2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)-1-(3-(3-methoxyureido)phenyl)ethyl)carbamate 
• 1454273-26-7 4-((3-(1-amino-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenyl)amino)butanoic acid 
• 1454273-83-6 ethyl 4-((3-(1-amino-2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1'-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4'-piperidin]-3(2H,4H,7H)-yl)ethyl)phenyl)amino)butanoate 

Relevant articles and documents

Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors

Abstract: Bacterial resistance represents a worldwide emergency threatening the efficacy of all available antibiotics. Among the several resistance mechanisms developed by bacteria, β-lactamase enzymes?(BLs), which are able to inactivate most β-lactam core antibiotics, represent a key target to block, thus prolonging antibiotics half-life. Several approaches aimed at inhibiting β-lactamases have been so far undertaken, mainly involving β-lactam-like or covalent inhibitors. Applying a structure-based de novo design approach, we recently discovered a novel, non-covalent and competitive inhibitor of AmpC β-lactamase:?lead 1. It has a Ki of 1 μM, a ligand efficiency of 0.38 kcal mol?1 and lead-like physical properties. Moreover, it reverts resistance to ceftazidime in bacterial pathogens expressing AmpC and does not up-regulate β-lactamases expression in cell culture. Its features make it a good candidate for chemical optimization: starting from lead 1 crystallographic complex with AmpC, 11 analogs were designed to complement additional AmpC sites, then synthesized and tested against clinically resistant pathogens. While the new inhibitors maintain similar in vitro activity as the starting lead, some of them, in biological assays, extert a higher potency showing improved synergic activity with ceftazidime in resistant clinically isolated strains. Graphical Abstract: [InlineMediaObject not available: see fulltext.].

GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.